BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 11032826)

  • 1. Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein.
    Jakubowiak A; Pouponnot C; Berguido F; Frank R; Mao S; Massague J; Nimer SD
    J Biol Chem; 2000 Dec; 275(51):40282-7. PubMed ID: 11032826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1.
    Sood R; Talwar-Trikha A; Chakrabarti SR; Nucifora G
    Leukemia; 1999 Mar; 13(3):348-57. PubMed ID: 10086725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The AML1/ETO fusion protein activates transcription of BCL-2.
    Klampfer L; Zhang J; Zelenetz AO; Uchida H; Nimer SD
    Proc Natl Acad Sci U S A; 1996 Nov; 93(24):14059-64. PubMed ID: 8943060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1.
    Frank RC; Sun X; Berguido FJ; Jakubowiak A; Nimer SD
    Oncogene; 1999 Mar; 18(9):1701-10. PubMed ID: 10208431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B.
    Frank R; Zhang J; Uchida H; Meyers S; Hiebert SW; Nimer SD
    Oncogene; 1995 Dec; 11(12):2667-74. PubMed ID: 8545124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.
    Vangala RK; Heiss-Neumann MS; Rangatia JS; Singh SM; Schoch C; Tenen DG; Hiddemann W; Behre G
    Blood; 2003 Jan; 101(1):270-7. PubMed ID: 12393465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis.
    Rhoades KL; Hetherington CJ; Rowley JD; Hiebert SW; Nucifora G; Tenen DG; Zhang DE
    Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11895-900. PubMed ID: 8876234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells.
    Mulloy JC; Cammenga J; MacKenzie KL; Berguido FJ; Moore MA; Nimer SD
    Blood; 2002 Jan; 99(1):15-23. PubMed ID: 11756147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different roles of E proteins in t(8;21) leukemia: E2-2 compromises the function of AETFC and negatively regulates leukemogenesis.
    Liu N; Song J; Xie Y; Wang XL; Rong B; Man N; Zhang MM; Zhang Q; Gao FF; Du MR; Zhang Y; Shen J; Xu CH; Hu CL; Wu JC; Liu P; Zhang YL; Xie YY; Liu P; Huang JY; Huang QH; Lan F; Shen S; Nimer SD; Chen Z; Chen SJ; Roeder RG; Wang L; Sun XJ
    Proc Natl Acad Sci U S A; 2019 Jan; 116(3):890-899. PubMed ID: 30593567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis.
    Sun XJ; Wang Z; Wang L; Jiang Y; Kost N; Soong TD; Chen WY; Tang Z; Nakadai T; Elemento O; Fischle W; Melnick A; Patel DJ; Nimer SD; Roeder RG
    Nature; 2013 Aug; 500(7460):93-7. PubMed ID: 23812588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML.
    Vegi NM; Klappacher J; Oswald F; Mulaw MA; Mandoli A; Thiel VN; Bamezai S; Feder K; Martens JHA; Rawat VPS; Mandal T; Quintanilla-Martinez L; Spiekermann K; Hiddemann W; Döhner K; Döhner H; Stunnenberg HG; Feuring-Buske M; Buske C
    Cell Rep; 2016 Jul; 16(2):498-507. PubMed ID: 27346355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
    Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
    Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Drosophila model identifies calpains as modulators of the human leukemogenic fusion protein AML1-ETO.
    Osman D; Gobert V; Ponthan F; Heidenreich O; Haenlin M; Waltzer L
    Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12043-8. PubMed ID: 19581587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional G-CSF pathways in t(8;21) leukemic cells allow for differentiation induction and degradation of AML1-ETO.
    Da Silva N; Meyer-Monard S; Menot ML; Parrado A; Lebel A; Balitrand N; Fenaux P; Micléa JM; Rousselot P; Degos L; Dombret H; Chomienne C
    Hematol J; 2000; 1(5):316-28. PubMed ID: 11920209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the ETO and AML1-ETO proteins involved in 8;21 translocation in acute myelogenous leukemia.
    Le XF; Claxton D; Kornblau S; Fan YH; Mu ZM; Chang KS
    Eur J Haematol; 1998 Apr; 60(4):217-25. PubMed ID: 9579874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis.
    Yan M; Ahn EY; Hiebert SW; Zhang DE
    Blood; 2009 Jan; 113(4):883-6. PubMed ID: 19036704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure of the AML1-ETO NHR3-PKA(RIIα) complex and its contribution to AML1-ETO activity.
    Corpora T; Roudaia L; Oo ZM; Chen W; Manuylova E; Cai X; Chen MJ; Cierpicki T; Speck NA; Bushweller JH
    J Mol Biol; 2010 Sep; 402(3):560-77. PubMed ID: 20708017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells.
    Kurokawa M; Mitani K; Imai Y; Ogawa S; Yazaki Y; Hirai H
    Blood; 1998 Dec; 92(11):4003-12. PubMed ID: 9834202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia.
    Li Y; Wang H; Wang X; Jin W; Tan Y; Fang H; Chen S; Chen Z; Wang K
    Blood; 2016 Jan; 127(2):233-42. PubMed ID: 26546158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia.
    Higuchi M; O'Brien D; Kumaravelu P; Lenny N; Yeoh EJ; Downing JR
    Cancer Cell; 2002 Feb; 1(1):63-74. PubMed ID: 12086889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.